Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Pembrolizumab in Advanced Metastatic Melanoma
NCT03957551Phase 2Terminated
- Start
- Aug 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in melanoma. Primary endpoints: Dose Limiting Toxicity at 21 days and Overall Response Rate at 2 years. Started Aug 2019; status: terminated.
02
Drugs
cabozantinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03957551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957551.